DL-01

• Description :

  DL-01 is a drug-linker conjugates for ADC that can be used for the synthesis of ADCs[1].

• UNSPSC :

  12352203

• Hazard Statement :

  H302-H315-H319-H335

• Target :

  Drug-Linker Conjugates for ADC

• Type :

  ADC Related

• Related Pathways :

  Antibody-drug Conjugate/ADC Related

• Applications :

  Cancer-programmed cell death

• Field of Research :

  Cancer

• Assay Protocol :

  https://www.medchemexpress.com/dl-01.html

• Solubility :

  DMSO : 100 mg/mL (ultrasonic)

• Smiles :

  CS(C1=NC=C(C=N1)C#CCCCC(N[C@@H](C(C)C)C(N[C@@H](CCCCN(CCC)CCC)C(NCC(NCOCCCC2=C3C(C(N4C3)=CC([C@](O)(C(OC5)=O)CC)=C5C4=O)=NC6=CC(OCO7)=C7C=C62)=O)=O)=O)=O)(=O)=O

• Molecular Formula :

  C55H71N9O13S

• Molecular Weight :

  1098.27

• Precautions :

  P261-P264-P270-P271-P280-P302+P352-P304+P340-P305+P351+P338-P330-P362+P364-P403+P233-P405-P501

• References & Citations :

  [1]Yonghan Hu, et al. Antibody, antibody-drug conjugate thereof and use thereof. Patent WO2023046202A1.

• Shipping Conditions :

  Blue Ice

• Storage Conditions :

  -20°C (Powder, protect from light, stored under nitrogen)

• Scientific Category :

  ADC Related

• Clinical Information :

  No Development Reported

• CAS Number :

  [2821770-49-2]